June 30, 2009
Solvay is aboard the Solar Impulse
Solvay’s know how, innovative solutions and ultrahigh-performance polymers are contributing to the Solar Impulse airplane [EN]-[FR]-[NL]
June 25, 2009
Inergy Automotive Systems brings two innovations which are reducing environmental impact of cars
The Solvay and Plastic Omnium joint venture innovates with SCR system which strongly reduces concentration of nitrogen oxides in diesel exhaust gasses,... [EN]-[FR]-[NL]
June 18, 2009
Inergy Automotive Systems is building new factories in China and India to serve growing automotive markets
The Solvay and Plastic Omnium joint venture reinforces its presence at the heart of the fast-growing automotive industry in Asia [EN]-[FR]-[NL]
June 10, 2009
Solvay Pharmaceuticals Inc. has been informed of ANDA filing for generic Androgel® in the USA
Attempt to seek approval for a generic version of Androgel® (testosterone gel) 1% CIII [EN]-[FR]-[NL]
June 04, 2009
Solvay Indupa successfully completes upgrade and expansion of its vinyl activities in Brazil
Solvay strengthens competitiveness of its PVC plant at Santo André, Brazil [EN]-[FR]-[NL]
May 20, 2009
Solvay will early close its public offering of a 6 year bond for a total amount of EUR 500 million
Solvay S.A. announces today that it will early close on Wednesday 20 may at the end of the business day its 6 year bond issue for a total amount of EUR 500 million. [EN]-[FR]-[NL]
May 15, 2009
Public offering of a 6 year bond bearing interest at 5.0 % issued by Solvay S.A. for an expected amount of minimum EUR 150 million
The Solvay Group announces today that it will issue through Solvay S.A. a 6 year bond for a minimum total amount of EUR 150 million in the form of a public offering in Belgium and Luxembourg. The bonds will bear interest at an annual gross rate of 5.0%. [EN]-[FR]-[NL]
May 12, 2009
Annual Shareholders Meeting 2009
Speeches by the Chairmen - Discours des Présidents - Toespraken van de Voorzitters [EN]-[FR]-[NL]
May 12, 2009
First quarter 2009 results
Good resilience of operating result (EUR 142 million) in the first quarter, up from the fourth quarter of 2008 (EUR 125 million). Due to the global crisis, a decrease compared to the high result of the first quarter of 2008 (EUR 300 million) [EN]-[FR]-[NL]
May 11, 2009
Electrolysis: Solvay licenses out energy saving technology to Uhde
Solvay-patented processes for brine treatment increases membrane life and cuts effluents of new plants [EN]-[FR]-[NL]
April 22, 2009
Note about the press release published on April 1st
Solvay confirms it is proceeding with an analysis of various options for its pharmaceutical activities. [EN]-[FR]-[NL]
April 14, 2009
Ms. Petra Mateos-Aparicio Morales and Mr. Hervé Coppens d’Eeckenbrugge are proposed to join Solvay’s Board of Directors [EN]-[FR]-[NL]
April 09, 2009
Chairmen's statement
"Managing Challenges" [EN]-[FR]-[NL]
April 01, 2009
Solvay confirms it is proceeding with an analysis of various options for its pharmaceutical activities
Solvay Group wishes to react to the rumours reported today in a press article. [EN]-[FR]-[NL]
March 10, 2009
Solvay announces the startup of SolVin’s new production capacity for Diofan® PVDC latex at its Tavaux plant
Construction completed ahead of schedule to serve food & pharmaceutical packaging industrie [EN]-[FR]-[NL]
February 19, 2009
2008 Results
2008 operating result (EUR 965 million) down by 19% compared to the record result of 2007. Fourth quarter affected by economic crisis and inventory depreciation. [EN]-[FR]-[NL]
December 16, 2008
Solvay welcomes FDA approval for Trilipix™ (fenofibric acid)
New therapy in combination with a statin helped patients improve HDL and LDL cholesterol and triglycerides in clinical studies [EN]-[FR]-[NL]
December 03, 2008
Solvay takes stake in fuel cell developer ACAL Energy
Investment in innovative low-cost and high reliability fuel cell technology [EN]-[FR]-[NL]
December 02, 2008
Solvay succesfully completes pre-registration of 400 substances in accordance with the REACH regulation (EC) no 1907/2006
Pre-registration is first main step in Solvay’s commitment to fulfill REACH obligations for its products [EN]-[FR]-[NL]
November 27, 2008
Solvay’s management and European Works Council are committing to sustainable development and corporate social responsibility
The CEO and the European Works Council sign a unique charter [EN]-[FR]-[NL]
November 17, 2008
Solvay Pharmaceuticals discontinues R&D activities of its anti-obesity compound SLV319
Solvay Pharmaceuticals announced today its decision to discontinue all R&D activities for its investigational compound SLV319. [EN]-[FR]-[NL]
November 13, 2008
Solvay Group holds 95.33% of Innogenetics shares
Solvay will proceed with squeeze-out of remaining Innogenetics shares and request delisting. [EN]-[FR]-[NL]
October 30, 2008
Nine months 2008 results
Operating results for Solvay Group (EUR 840 million) down by 9% compared to the excellent results of the first nine months 2007. Good resistance in the third quarter (-6%) [EN]-[FR]-[NL]
October 17, 2008
Solvay acquires Alexandria Sodium Carbonate company in Egypt
Expansion into growing Egyptian, Middle Eastern and North-African markets [EN]-[FR]-[NL]
October 15, 2008
Solvay sets ambitious goals for its Sustainable Development
Quantified Targets to Curb the Environmental Impact of the Group’s Activities and Products [EN]-[FR]-[NL]
October 15, 2008
Solvay Group holds 93.1% of Innogenetics
Offer on Innogenetics shares is extended from 22 October to 12 November [EN]-[FR]-[NL]
October 06, 2008
Solvay CEO Christian Jourquin elected President of Cefic
"The Chemical Industry: a Solution Provider" [EN]-[FR]-[NL]
October 01, 2008
Solvay Investors Day
Presentations [EN]
September 29, 2008
Solvay invests EUR 55 milion in reduced electricity consumption and lower environmental impact of its electrolytic unit at Tavaux (F)
Launch of membrane-based electrolytic technology [EN]-[FR]-[NL]
September 25, 2008
Solvay Solexis enters joint development agreement with Strategic Polymer Sciences to develop ultra-high-energy density capacitator materials
New materials increase efficiency of energy storage and medical therapeutics [EN]-[FR]-[NL]
September 24, 2008
Solvay strengthens position in fluorinated high-performance materials in Asia
Second world-class production plant of Polytetrafluoroethylene Micronised Powder [EN]-[FR]-[NL]
September 11, 2008
Vinythai : Solvay’s vinyls affiliate in Thailand increases PVC production capacity
Vinythai strengthens its position as a fully integrated world class PVC producer [EN]-[FR]-[NL]
September 09, 2008
Solvay Pharmaceuticals acquires Innogenetics
Solvay Group holds 84.3% of Innogenetics shares [EN]-[FR]-[NL]
September 04, 2008
Solvay Indupa secures competitive & reliable energy sourcing in Argentina
Alliance with Energy Group Albanesi for the Construction of a New Power Plant [EN]-[FR]-[NL]
August 13, 2008
Umicore and Solvay foster zero emission car racing team
Two established Belgian names sponsor Belgian fuel cell powered racing kart [EN]-[FR]-[NL]
July 31, 2008
First half 2008 results
Operating results for the Solvay Group for the 1st half of 2008: -11% compared to the high level of the 1st half of 2007 - Sustained level of activities - increased energy and raw materials costs [EN]-[FR]-[NL]
July 24, 2008
Solvay Pharmaceuticals S.A. plans the offer period for Innogenetics from August 12 to September 5, 2008
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, the chemical and pharmaceutical group, today announced that it plans the offer period to acquire Innogenetics N.V., a Belgian-based biotechnological company, from August 12 to September 5, pending approval of the takeover prospectus by Belgium’s Banking, Finance and Insurance Commission (CBFA). [EN]-[FR]-[NL]
July 09, 2008
Solvay Pharmaceuticals S.A. increases to eur 6.50 per share its initial tender offer to acquire Innogenetics
Solvay Pharmaceuticals S.A., a subsidiary of Solvay, the chemical and pharmaceutical group, today announced that it will increase its initial conditional tender offer to acquire Innogenetics N.V., a Belgian-based biotechnological company, in a cash transaction valued at EUR 6.50 per share. [EN]-[FR]-[NL]
June 26, 2008
Inergy Automotive Systems starts operations in China
The Solvay / Plastic Omnium joint venture at the heart of a fast-growing industry
[EN]-[FR]-[NL]
June 19, 2008
Solvay's Tavaux (France) Plant to be powered with biomass-based energy
A sustainable and competitive alternative to fossil fuels [EN]-[FR]-[NL]
June 02, 2008
Phase III study of investigational TRILIPIX™ (SLV348/ABT-335), in combination with Astrazeneca’s CRESTOR® meets primary endpoints on key lipids
TriLipix™ in combination with Crestor® improved LDL, HDL and Triglycerides and had reported safety consistent with monotherapies
[EN]-[FR]-[NL]
May 21, 2008
Solvay joins Capricorn‘Cleantech’venture capital fund
Exploring new business developments in sustainable technologies [EN]-[FR]-[NL]
May 14, 2008
Solvay launches new product for air pollution control
Investing USD 40 Million in Innovative Technology to Manufacture SOLVAir ® Select 300 for Flue Gas Treatment [EN]-[FR]-[NL]
May 13, 2008
First quarter 2008 results
Operating results for the Solvay Group in the 1st quarter of 2008 : -8% compared to the high level of the 1st quarter of 2007. An increase of 12% compared to the 4th quarter of 2007. Net income of the Group (eur 220 million) up by 1%. [EN]-[FR]-[NL]
May 13, 2008
Annual Shareholders Meeting 2008
Speeches by the Chairmen - Toespraken van de Voorzitters - Discours des Présidents [EN]-[FR]-[NL]
May 08, 2008
Solvay to power its Bernburg (Germany) plant with secondary solid fuels
Energy generated from Refuse Derived Fuel Available in 2010 [EN]-[FR]-[NL]
April 25, 2008
SOLVAY PHARMACEUTICALS S.A. LAUNCHES FRIENDLY BID TO ACQUIRE INNOGENETICS
Building on a successful R&D co-operation [EN]-[FR]-[NL]
March 31, 2008
Phase III studies of investigational Trilipix™ (SLV348/ABT-335), in combination with statins, meets primary endpoints on improving LDL, triglycerides and HDL
TriLipix™ in combination with statins improved all three key lipids and had reported safety consistent
with TriLipix™ or statin monotherapies
[EN]-[FR]-[NL]
March 12, 2008
FDA approval of Abbott's SIMCOR® marks start of co-promotion with Solvay
FDA Decision Triggers Milestone Payment of USD 100 million by Solvay to Abbott [EN]-[FR]-[NL]
March 06, 2008
Solvay finalized sale of polypropelene compounding activity to Lyondellbasell
Solvay announces today that it has finalized the sale of 100% of its subsidiary Solvay Engineered Polymers (SEP), a major supplier of polypropylene compounds, to LyondellBasell Industries. [EN]-[FR]-[NL]
March 03, 2008
Fournier Laboratories Ireland Ltd and Laboratoires Fournier SA filed patent infringement actions against Teva in the USA
Fournier Laboratories asserts intellectual property of TriCor® (fenofibrate) 145mg NFE [EN]-[FR]-[NL]
February 29, 2008
Solvay Pharmaceuticals S.A. acknowledges decision of Wyeth Pharmaceuticals to terminate the collaboration agreement on bifeprunox
Solvay Pharmaceuticals will evaluate all options for the future of the compound [EN]-[FR]-[NL]
February 15, 2008
2007 Results
Record operating results for Solvay in 2007 of EUR 1.2 billion, up 9% from 2006 [EN]-[FR]-[NL]
February 01, 2008
Sale of Solvay’s Caprolactones business to Perstorp confirmed
Transaction Received European Commission Antitrust Clearance [EN]-[FR]-[NL]
January 23, 2008
Fournier Laboratories Ireland Ltd was informed of anda filing for generic Tricor® in the USA
An Attempt to Seek Approval for a Generic Version of TriCor® 145mg NFE Tablets [EN]-[FR]-[NL]
December 14, 2007
Solvay Indupa will produce bioethanol-based vinyl in Brasil & considers state-of-the-art power generation in Argentina
Polyvinyl chloride (PVC) Derived from Sugar Cane and Salt [EN]-[FR]-[NL]
November 30, 2007
Solvay Science for Innovation Conference focuses on the creation of novel, complex materials
Nobel Prize Winners Lehn and Laughlin Address Solvay Researchers [EN]-[FR]-[NL]
November 29, 2007
Solvay signs agreement to sell polypropylene compounding activity to Basell
Focusing on activities where the Group has better opportunities to create business value [EN]-[FR]-[NL]
November 07, 2007
New clinical data show Solvay’s fenofibrate cuts risk of main causes of vision loss in patients with type 2 diabetes
Fenofibrate offers opportunity to protect patients from most serious consequences of type 2 diabete [EN]-[FR]-[NL]
October 30, 2007
SolVin Awards acclaim vinyl innovators at K2007 for environmental, design and safety achievements
The winners of the 2007 SolVin Awards for PVC Innovation were unveiled yesterday during the K2007 International Plastics Trade Fair in Düsseldorf, Germany, honouring the most impressive innovators among 107 contestants which represented the entire vinyl value chain. [EN]
October 29, 2007
Solvay takes steps to resume growth and restore competitiveness of its Fluor Chemicals business
Focusing on high value added specialties, downsizing production of commodities [EN]-[FR]-[NL]
October 26, 2007
Nine months 2007 results
Solvay’s operating results (EUR 925 million) 5% above the excellent results from the first 9 months of 2006 (+8% in the 3rd quarter) [EN]-[FR]-[NL]
October 24, 2007
Solvay Unveils 'More Plastics with More Performance' at K2007 International Plastics Trade Fair
Solvay announces today that it has unveiled a number of innovative products at a press conference on the opening of the K2007 International Plastics Trade Fair in Düsseldorf, Germany, including the new family of SolvivaTM Biomaterials available for use in implantable medical devices as well as extensions to its Hyflon® and Tecnoflon® fluoropolymers ranges. [EN]-[FR]-[NL]
October 22, 2007
Abbott and Solvay Pharmaceuticals to co-promote Abbott's SIMCOR® in the United States
Solvay Pharmaceuticals has entered into an agreement granting Solvay select co-promotion rights in the United States for Abbott's investigational fixed-dose combination lipid therapy, SIMCOR® (Niaspan®/simvastatin), currently awaiting U.S. Food and Drug Administration (FDA) approval. [EN]-[FR]-[NL]
October 17, 2007
Pipelife starts up production in new russian factory
Solvay Affiliate Expands into One of Europe’s Fastest Growing Markets [EN]-[FR]-[NL]
October 15, 2007
Solvay signs agreement to sell Caprolactones business to Perstorp
Focusing on activities where the Group has maximum control over raw materials [EN]-[FR]-[NL]
October 08, 2007
China : Solvay reinforces its presence and plans for more investments in specialty polymers
PTFE Micronized Powder facility confirmed; more projects under consideration [EN]-[FR]-[NL]
September 26, 2007
Solvay Investors Day
Presentations [EN]
September 24, 2007
Solvin to expand PVDC latex production in world-class plant of Tavaux (France)
A timely, competitive response to serve growing demand from food & pharma industry [EN]-[FR]-[NL]
September 06, 2007
Solvay to build world-class Epicerol® plant in Thailand
Innovative green chemistry technology to serve strong demand for epichlorohydrin [EN]-[FR]-[NL]
August 30, 2007
Solvay expands printed electronics development platform with investment in Plextronics
Innovative Technology for Mass-Production of Displays, Lighting, Solar Cells and ‘Smart’ Labels [EN]-[FR]-[NL]
August 14, 2007
Solvay launches Peracetic Acid production in China
State-of-the-Art Proxitane® Plant now fully operational in Suzhou [EN]-[FR]-[NL]
August 10, 2007
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals announce receipt of an FDA action letter for bifeprunox, an investigational treatment for schizophrenia
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today the receipt of an action letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for bifeprunox, an atypical antipsychotic that was reviewed for the acute treatment of schizophrenia, as well as the maintenance of stable adult patients. [EN]-[FR]-[NL]
July 30, 2007
Dow and Solvay Form Joint Venture to Build Hydrogen Peroxide Plant in Thailand; Dow and BASF Continue to Pursue Plans for Thailand HPPO Plant [EN]-[FR]-[NL]
July 27, 2007
First half 2007 results
Solvay’s operating results of EUR 616 million for the 1st half of 2007, exceeding the excellent results for the 1st half of 2006 [EN]-[FR]-[NL]
July 24, 2007
SOLVIN moves to reap sustainable benefits from dynamic vinyls market
Focus on highly competitive production units [EN]-[FR]-[NL]
June 28, 2007
SOLVAY, SIBUR sign join venture agreement to build Russia’s first world-scale vinyls production plant
State-of-the art technology for a fast-growing market [EN]-[FR]-[NL]
June 22, 2007
Solvay Sodi expands soda ash production capacity in Devnya (Bulgaria) to provide for the growth of its clients
10th Anniversary of Privatization Highlights Success Story [EN]-[FR]-[NL]
June 14, 2007
Solvay and Thin Film Electronics sign agreement to develop and optimize materials for printed memories
Printed electronics pave way for major technological breakthrough with multiple new applications [EN]-[FR]-[NL]
May 22, 2007
With the Queen Elisabeth Medical Foundation, Solvay supports the fight against Charcot-Marie-Tooth disease
The quest to treat more effectively a neuro-degenerative disorder that affects one person in 2,500 [EN]-[FR]-[NL]
May 08, 2007
First quarter 2007 results
Further growth in operating results for the Solvay Group : +11% in the first quarter of 2007 [EN]-[FR]-[NL]
May 08, 2007
Annual Shareholders Meeting 2007
Speeches by the Chairmen - Toespraken van de Voorzitters - Discours des Présidents [EN]-[FR]-[NL]
May 07, 2007
Inergy Automotive Systems deploys its fuel systems business in China, India and Russia
The Solvay / Plastic Omnium joint venture supplies its automotive customers on strong-growth markets [EN]-[FR]-[NL]
May 02, 2007
Solvay Solexis expands Polyvinyledene fluoride (PVDF) production capacity in Tavaux (France)
Marketing and R&D efforts boost demand for SOLEF® [EN]-[FR]-[NL]
April 25, 2007
Solvay Pharmaceuticals files TEDISAMIL, a new cardiometabolic product for the treatment of atrial fibrillation and atrial flutter
Solvay announced today that its dossier for intravenous tedisamil (intended brand name: PULZIUM® IV), a new chemical entity coming from Solvay Pharmaceuticals R&D laboratories, has been filed for approval by the US Food and Drug Administration (FDA) as well as by the authorities of European Union countries. This means that the formal processing and review have begun. [EN]-[FR]-[NL]
April 05, 2007
Solvay’s green chemistry technology for the manufacturing of Epichlorohydrin is operational in Tavaux (France)
Group consolidates technological leadership of Epicerol™ process [EN]-[FR]-[NL]
April 02, 2007
Solvay affiliate Pipelife acquires Quality Plastics, a specialty pipes & fittings manufacturer
Pipelife reinforces product portfolio in fast-growing market, broadens geographical [EN]-[FR]-[NL]
March 30, 2007
SolVin considers new PVDC latex production unit
Serving Growing demand for barrier material [EN]-[FR]-[NL]
February 22, 2007
Solvay Solexis expands perfluoropolyethers (PFPE) production capacity in Spinetta Marengo (Italy)
Strong demand & growth prospects for innovative products Solvera®, Fluorolink® & H-Galden® [EN]-[FR]-[NL]
February 19, 2007
Solvay statement on press article published in « Vers l’Avenir” on February 19, 2007 [EN]-[FR]
February 15, 2007
2006 Results
2006 : another record year for Solvay,due to strong growth in operating performance. Growth in sales of 10% and in operating results of 21% [EN]-[FR]-[NL]
